Skip to main content
. 2019 Nov;23(Suppl 1):S5–S83.

Table 1.

Statistical analysis of severe hypoglycemia across diabetes duration categories and treatment arms

<10 years 10-15 years 15-20 years ≥20 years




IGlar U100
(n=986)
Degludec
(n=906)
IGlar U100
(n=938)
Degludec
(n=912)
IGlar U100
(n=769)
Degludec
(n=805)
IGlar U100
(n=1126)
Degludec
(n=1195)
Number and proportion of
patients with SH, n (%)
54 (5.5) 29 (3.2) 45 (4.8) 46 (5.0) 50 (6.5) 35 (4.3) 103 (9.1) 77 (6.4)
Rate of SH 4.5 2.5 5.7 4.5 4.9 3.6 9.7 5.0
Relative risk of SH (degludec vs. IGlar) (95% CI) 0.48 (0.29-0.81) 0.76 (0.48-1.21) 0.68 (0.40-1.14) 0.52 (0.35-0.77)

Degludec: Insulin degludec; IGlar U100: Insulin glargine 100 units/mL; Rate: Events per 100 patient-years of observation; SH: Severe hypoglycemia; CI: Confidence interval